BR112022015818A2 - Preparação de um antagonista de p2x3 - Google Patents

Preparação de um antagonista de p2x3

Info

Publication number
BR112022015818A2
BR112022015818A2 BR112022015818A BR112022015818A BR112022015818A2 BR 112022015818 A2 BR112022015818 A2 BR 112022015818A2 BR 112022015818 A BR112022015818 A BR 112022015818A BR 112022015818 A BR112022015818 A BR 112022015818A BR 112022015818 A2 BR112022015818 A2 BR 112022015818A2
Authority
BR
Brazil
Prior art keywords
antagonist
preparation
processes
methylimidazo
methylcarbamoyl
Prior art date
Application number
BR112022015818A
Other languages
English (en)
Inventor
Chauret Nathalie
Green Jeremy
R Kronenthal David
Villeneuve Karine
Original Assignee
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc filed Critical Bellus Health Cough Inc
Publication of BR112022015818A2 publication Critical patent/BR112022015818A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PREPARAÇÃO DE UM ANTAGONISTA DE P2X3. São aqui descritos dois processos para a preparação de (S)-2-((2-(2,6-difluoro-4-(metilcarbamoil)fenil)-7-metilimidazo[1,2-a]piridin-3-il)metil)morfolina-4-carboxilato de metila, um antagonista de P2X3, em etapas, e intermediários químicos usados nos processos sintéticos.
BR112022015818A 2020-02-14 2021-02-12 Preparação de um antagonista de p2x3 BR112022015818A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977004P 2020-02-14 2020-02-14
US202163144902P 2021-02-02 2021-02-02
PCT/IB2021/000130 WO2021161109A1 (en) 2020-02-14 2021-02-12 Preparation of a p2x3 antagonist

Publications (1)

Publication Number Publication Date
BR112022015818A2 true BR112022015818A2 (pt) 2022-10-25

Family

ID=77292130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015818A BR112022015818A2 (pt) 2020-02-14 2021-02-12 Preparação de um antagonista de p2x3

Country Status (11)

Country Link
US (1) US20230101612A1 (pt)
EP (1) EP4103572A4 (pt)
JP (1) JP2023513738A (pt)
KR (1) KR20220140804A (pt)
CN (1) CN115427419A (pt)
AU (1) AU2021219992A1 (pt)
BR (1) BR112022015818A2 (pt)
CA (1) CA3184277A1 (pt)
IL (1) IL295394A (pt)
MX (1) MX2022009765A (pt)
WO (1) WO2021161109A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022156784A1 (zh) * 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体
WO2022156783A1 (zh) * 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物的制备方法及其中间体
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2024042471A1 (en) * 2022-08-25 2024-02-29 14245563 Canada Inc. Preparation of a p2x3 antagonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2951177B1 (en) * 2013-01-31 2018-04-04 Neomed Institute Imidazopyridine compounds and uses thereof
JP2022515879A (ja) * 2018-12-29 2022-02-22 武漢朗来科技発展有限公司 複素環式化合物、中間体、その製造方法及び応用 本願は、出願日が２０１８年１２月２９日の中国特許出願ｃｎ ２０１８１１６４２３１９、出願日が２０１９年０５月２４日の中国特許出願ｃｎ２０１９１０４４０２１４．３及び出願日が２０１９年１０月２４日の中国特許出願ｃｎ２０１９１１０１６１５８．７に基づいて優先権を主張する。また、上記中国特許出願の全文は本願に援用される。

Also Published As

Publication number Publication date
JP2023513738A (ja) 2023-04-03
EP4103572A4 (en) 2024-03-06
KR20220140804A (ko) 2022-10-18
CN115427419A (zh) 2022-12-02
CA3184277A1 (en) 2021-08-19
IL295394A (en) 2022-10-01
US20230101612A1 (en) 2023-03-30
AU2021219992A1 (en) 2022-09-01
WO2021161109A1 (en) 2021-08-19
MX2022009765A (es) 2022-09-09
EP4103572A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
BR112022015818A2 (pt) Preparação de um antagonista de p2x3
CL2020003047S1 (es) Interfaz de herramienta eléctrica. (divisional de solicitud 201903643)
DK3800189T3 (da) Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
EP3587422A4 (en) PYRROLO-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE-RELATED DISEASE
EA200500530A1 (ru) Фармацевтическая композиция амфетамина и/или его солей (варианты) и способ лечения нарушений типа гиперактивности при дефиците внимания с ее использованием (варианты)
DK2289514T3 (da) Pramipexol-doseringsform til anvendelse én gang dagligt
BRPI0511695A (pt) agonistas de receptor (beta)2 adrenérgico diamina
CY1117023T1 (el) Διεργασια για την παρασκευη τροποποιημενων ηλεκτροδιων, ηλεκτροδια παρασκευασμενα με την εν λογω διεργασια και ενζυμικοι βιοαισθητηρες που περιλαμβανουν τα εν λογω ηλεκτροδιa
BR122018014454B8 (pt) forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
ME00230B (me) 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni
DK3979876T3 (da) Bærbar stol
MD3687996T2 (ro) Săruri de derivați de pirolotriazină utile ca inhibitori TAM
MA55608A (fr) Procédés de traitement d'un lymphome non hodgkinien à l'aide de la 2-(2,6-dioxopipéridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazétidin-1-yl)méthyl)benzyl)amino)isoindoline-1,3-dione
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
EE200300381A (et) Laiaspektrilised 2-(asendatud amino)bensotiasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
CL2020001856A1 (es) Métodos para tratar la enfermedad de farber.
CL2021002736S1 (es) Herramienta eléctrica. (divisional solicitud 201903646)
CL2021002738S1 (es) Cargador de batería para herramienta eléctrica. (divisional solicitud 202000568)
WO2007101274A3 (en) Mycobacterial disease detection, treatment, and drug discovery
EE200300494A (et) Laiaspektrilised 2-(asendatud amino)bensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
SI3724176T1 (sl) Fumaratna sol (R)-3-(1-(2,3-dikloro-4-(pirazin-2-il)fenil)-2,2,2-trifluoroetil)-1 -metil-1-(1-metilpiperidin-4-il) sečnine, postopki priprave in uporabe le-te
ATE482952T1 (de) Ethanolaminsalz von n-(methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid
WO2021080931A8 (en) Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
BR112014007758A2 (pt) composto à base de fenilisoxazolina orto-substituído, com 2,6-difluorobenziloximetil, método e uso do mesmo
MA56126A (fr) Mélanges de protéines à base de plantes et compositions nutritionnelles